The demand for small-scale fill-finish services is rapidly expanding as the pharmaceutical industry shifts toward more ...

The new framework comes amid frail times for rare disease drug research in the US. The US Food and Drug Administration (FDA) ...

The US Food and Drug Administration (FDA) approval of Insmed’s Brinsupri marks a significant advancement in the treatment ...

Avadel has signed an exclusive worldwide licencing deal with XWPharma for the development and commercialisation of ...

For Novartis, the Argo deal marked the second billion-dollar RNA-based deal in a day. A few hours prior, the company ...

Health Canada has granted approval to AbbVie's ADC, Elahere, to treat adults with certain types of ovarian cancers.

Despite a trial failure in Parkinson’s disease, Novartis is having a second bite of the alpha-synuclein cherry with Arrowhead’s drug.

Morocco’s pharmaceutical sector will undergo a major change as the country prepares for the introduction of a new drug ...

Amgen is set to invest $600m for the construction of a new centre for science and innovation in its US global headquarters.

Effectively transitioning a drug manufacturing process to a CDMO always depends on strong communication and well-defined ...

Quotient Sciences has entered a partnership with the UK's CPI to expedite the creation of RNA-based treatments ...

With Novo Nordisk’s semaglutide patent set to expire in China in 2026, local companies are readying generics to grasp market ...